Cough in Idiopathic Pulmonary Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cough in Idiopathic Pulmonary Fibrosis pipeline constitutes 5+ key companies continuously working towards developing 5+ Cough in Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report: https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Cough in Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
• Cough in Idiopathic Pulmonary Fibrosis companies working in the treatment market are NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others, are developing therapies for the Cough in Idiopathic Pulmonary Fibrosis treatment
• Emerging Cough in Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others are expected to have a significant impact on the Cough in Idiopathic Pulmonary Fibrosis market in the coming years.
• In September 2025, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical firm advancing HaduvioTM (oral nalbuphine ER) for chronic cough linked to idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), announced that results from its Phase 2a RIVER trial in RCC will be showcased in two poster presentations at the European Respiratory Society (ERS) Congress 2025, taking place from September 27 to October 1 in Amsterdam, Netherlands.
• In March 2025, Trevi Therapeutics, the U.S.-based company developing nalbuphine extended-release (ER) tablets, announced the completion of enrollment in the Phase 2b clinical trial, known as CORAL. The trial is evaluating the therapy, which is intended to be marketed as Haduvio, in individuals with idiopathic pulmonary fibrosis (IPF) who experience chronic cough. This milestone marks a significant step forward in the development of Haduvio for IPF patients dealing with chronic cough.
• In February 2025, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on developing HaduvioTM (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced the completion of patient enrollment in its Phase 2b CORAL trial evaluating Haduvio for chronic cough in IPF patients.
• In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel, first-in-class human IgG1 antibody aimed at inhibiting WISP1-mediated fibrotic signaling, which plays a role in multiple debilitating diseases.
• In December 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on developing the investigational treatment HaduvioTM (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced a positive result from the planned sample size re-estimation (SSRE) for its ongoing Phase 2b CORAL trial in IPF patients with chronic cough. The outcome indicates that no adjustments are needed to the current sample size for the trial (N=160).
• In August 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced that the majority of the 60 planned sites for the Phase 2b CORAL trial have been initiated. The trial, which aims to enroll around 160 patients, will include a sample size re-estimation (SSRE) in the fourth quarter of this year, once 50% of patients are evaluable for the primary endpoint. Barring any adjustments, topline results are expected in the first half of 2025.
• In May 2024, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has announced topline results from a 12-week, randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) conducted at Massachusetts General Hospital. The trial evaluated changes in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF), a condition marked by excessive collagen buildup in the lungs.
• In March 2024, US-based Seyltx finalized an agreement to acquire Algernon Pharmaceuticals' chronic cough therapy, ifenprodil (NP-120). Algernon received $2 million and a 20% equity stake in Seyltx as part of the deal. Ifenprodil, an N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA type subunit 2B (GluN2B). Data from the Phase II trial conducted in Australia and New Zealand demonstrated a reduction in cough count among patients with idiopathic pulmonary fibrosis (IPF) and chronic cough compared to baseline.

Cough in Idiopathic Pulmonary Fibrosis Overview
Cough in Idiopathic Pulmonary Fibrosis (IPF) is a common and distressing symptom of this chronic lung disease. IPF causes scarring and thickening of the lung tissue, leading to breathing difficulties and persistent dry, non-productive cough. The exact cause of cough in IPF is not fully understood, but it is believed to result from the irritation caused by the fibrosis (scarring) of the lung tissue, which can trigger the cough reflex. This cough is often persistent, worsening over time, and can significantly impact a patient's quality of life. Treatment typically focuses on managing symptoms and slowing the progression of IPF.

Get a Free Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Cough in Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:
• Orvepitant Maleate: NeRRe Therapeutics
• Haduvio (nalbuphine ER): Trevi Therapeutics
• ME-015 (Suplatast Tosilate): Melius Pharma AB
• BI 1839100: Boehringer Ingelheim

Cough in Idiopathic Pulmonary Fibrosis Route of Administration
Cough in Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Cough in Idiopathic Pulmonary Fibrosis Molecule Type
Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment
• Cough in Idiopathic Pulmonary Fibrosis Assessment by Product Type
• Cough in Idiopathic Pulmonary Fibrosis By Stage and Product Type
• Cough in Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
• Cough in Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
• Cough in Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
• Cough in Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight's Cough in Idiopathic Pulmonary Fibrosis Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Cough in Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Cough in Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Cough in Idiopathic Pulmonary Fibrosis therapies
https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market include:
Key companies developing therapies for Cough in Idiopathic Pulmonary Fibrosis are - Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, NeRRe Therapeutics, Trevi Therapeutics, Cellular Sciences, Emphycorp, and others

Cough in Idiopathic Pulmonary Fibrosis Pipeline Analysis:
The Cough in Idiopathic Pulmonary Fibrosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.
• Cough in Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis drugs and therapies
https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Drivers
• High Unmet Need, Growing Patient Population, Advancements in Research, Regulatory Support, Increased Investment, are some of the important factors that are fueling the Cough in Idiopathic Pulmonary Fibrosis Market.

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Barriers
• However, Complex Disease Pathophysiology, Clinical Trial Challenges, Competitive Landscape, and other factors are creating obstacles in the Cough in Idiopathic Pulmonary Fibrosis Market growth.

Scope of Cough in Idiopathic Pulmonary Fibrosis Pipeline Drug Insight
• Coverage: Global
• Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others
• Key Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others
• Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies
• Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.